The prevalence of pyrazinamide resistance in multidrug resistant tuberculosis cases in the Netherlands Source: Annual Congress 2012 - Microbiological advances in the diagnosis of tuberculosis Year: 2012
Comparative analysis between multidrug resistant tuberculosis (MDR-TB) and extensively drug resistant tuberculosis (XDR-TB) in HIV(+) patients Source: Annual Congress 2009 - Tuberculosis and HIV co-infection Year: 2009
Treatment of multidrug resistant pulmonary tuberculosis (MDR-TB) with different pattern of resistance Source: Eur Respir J 2004; 24: Suppl. 48, 723s Year: 2004
Treatment possibilities of multi-drug resistant (MDR) tuberculosis Source: Eur Respir J 2003; 22: Suppl. 45, 525s Year: 2003
Evaluation of a molecular assay for detection of rifampin and isoniazid resistant mycobacterium tuberculosis in strains and clinical samples Source: Annual Congress 2008 - Genetics, immunology and microbiology of tuberculosis Year: 2008
Our experience in multi drug resistant tuberculosis (MDR TB) treatment Source: Eur Respir J 2005; 26: Suppl. 49, 652s Year: 2005
Treatment results of multidrug resistant pulmonary tuberculosis (MDR-TB) Source: Eur Respir J 2005; 26: Suppl. 49, 199s Year: 2005
Direct molecular testing for isoniazid and rifampicin resistance from respiratory specimens of patients with tuberculosis Source: Annual Congress 2013 –Tuberculosis: epidemiology and public health management III Year: 2013
Relationship between rpoB mutations and minimum inhibitory concentrations of rifampicin in multi drug resistant strains of mycobacterium tuberculosis Source: Annual Congress 2011 - Tuberculosis: from bench to bedside Year: 2011
Second-line anti-tuberculosis drug concentrations for susceptibility testing in the MODS assay Source: Eur Respir J 2013; 41: 1163-1171 Year: 2013
Efficacy and safety of linezolid for the treatment of multidrug resistant tuberculosis (MDR-TB) and disease by non tuberculous mycobacteria (NTM) Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011
Second and third line anti-tuberculosis drug's side effects during the treatment of patients with multidrug resistant tuberculosis (MDR TB) Source: Eur Respir J 2003; 22: Suppl. 45, 555s Year: 2003
Treatment of resistant tuberculosis in patients having isolates resistant to multiple antituberculosis drugs Source: Annual Congress 2010 - Prognosis of tuberculosis Year: 2010
Impact of resistance to first-line and injectable drugs on treatment outcomes in MDR-TB Source: Eur Respir J 2009; 33: 581-585 Year: 2009
Multidrug resistant tuberculosis (MDR – TB) treatment outcomes in Iran Source: Eur Respir J 2004; 24: Suppl. 48, 657s Year: 2004
Usefulness of a new molecular method to detect fluoroquinolones, kanamycin, capreomycin and ethambutol resistance in TB clinical isolates and direct specimens Source: Annual Congress 2010 - Tuberculosis: from bench to bedside Year: 2010
Shortened multidrug-resistant tuberculosis regimens overcome low-level fluoroquinolone resistance Source: Eur Respir J, 49 (6) 1700223; 10.1183/13993003.00223-2017 Year: 2017
Treatment outcome of multi-drug resistant tuberculosis Source: Annual Congress 2004 - Problems of resistance and HIV coinfection in tuberculosis Year: 2004
Surgical treatment of multidrug resistant pulmonary tuberculosis (MDR-TB) Source: Annual Congress 2009 - Treatment of tuberculosis at times of emerging drug resistance Year: 2009
Detection of isoniazid or rifampin resistant Mycobacterium tuberculosis in patients with cavity and previously treated for tuberculosis - usefulness of rapid drug susceptibility test with sputum samples by reverse hybridization assay Source: Annual Congress 2005 - Resistant and multidrug resistant tuberculosis Year: 2005